Effects of Tiotropium Combined with Theophylline on Stable COPD Patients of Group B, D and its Impact on Small Airway Function: A Randomized Controlled Trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2017 report [EB/OL](2016-11-16). http://www.goldcopd.org . Accessed 3 Jan 2017.
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. https://doi.org/10.1371/journal.pmed.0030442 .
Global strategy for the diagnosis, management, and prevention of COPD (revised 2011) [EB/OL] (2011-11). http://www.goldcopd.org . Accessed 2 Jan 2011.
Vestbo J, Vogelmeier C, Small M, Higgins V. Understanding the GOLD 2011 strategy as applied to a real-world COPD population. Resp Med. 2014;108(5):729–36. https://doi.org/10.1016/j.rmed.2014.03.002 .
Jones PW, Nadeau G, Small M, Adamek L. Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations. Resp Med. 2014;108(1):129–35. https://doi.org/10.1016/j.rmed.2013.08.015 .
Han MLK, Muellerova H, Curran-Everett D, Dransfield MT, Washko GR, Regan EA, Bowler RP, Beaty TH, Hokanson JE, Lynch DA, Jones PW, Anzueto A, Martinez FJ, Crapo JD, Silverman EK, Make BJ. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Resp Med. 2013;1(1):43–50. https://doi.org/10.1016/S2213-2600(12)70044-9 .
Soriano JB, Alfageme I, Almagro P, Casanova C, Esteban C, Soler-Cataluna JJ, de Torres JP, Martinez-Camblor P, Miravitlles M, Celli BR, Marin JM. Distribution and prognostic validity of the New Global Initiative for Chronic Obstructive Lung Disease grading classification. Chest. 2013;143(3):694–702. https://doi.org/10.1378/chest.12-1053 .
Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, Investigators US. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54. https://doi.org/10.1056/NEJMoa0805800 .
Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA, Investigators I. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26. https://doi.org/10.1164/rccm.200707-973OC .
Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, Investigators U. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171–8. https://doi.org/10.1016/S0140-6736(09)61298-8 .
Kanehara M, Yokoyama A, Tomoda Y, Shiota N, Iwamoto H, Ishikawa N, Taooka Y, Haruta Y, Hattori N, Kohno N. Anti-inflammatory effects and clinical efficacy of theophylline and tulobuterol in mild-to-moderate chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(6):874–8. https://doi.org/10.1016/j.pupt.2008.09.003 .
Berger R, Smith D. Acute postbronchodilator changes in pulmonary function parameters in patients with chronic airways obstruction. Chest. 1988;93(3):541–6.
Global strategy for the diagnosis, management, and prevention of COPD, update January 2015 [EB/OL]. http://www.goldcopd.org . Accessed 3 Jan 2015.
Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–5. https://doi.org/10.1164/rccm.201310-1863PP .
Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP, Investigators US. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(10):948–55. https://doi.org/10.1164/rccm.200906-0876OC .
Sampablo I, Carone M, Antoniu SA. Tiotropium therapy and mortality risk in COPD patients: the most severe, the most protected? Evaluation of Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180(10): 948-55. Expert Opin Pharmacother. 2010;11(8):1439–41. https://doi.org/10.1517/14656561003745916 .
Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM, Rabe KF, Fabbri LM, Investigators P-C. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093–103. https://doi.org/10.1056/NEJMoa1008378 .
Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD009157. https://doi.org/10.1002/14651858.cd009157.pub2 .
Suissa S, Dell’Aniello S, Ernst P. Long-acting bronchodilator initiation in COPD and the risk of adverse cardiopulmonary events a population-based comparative safety study. Chest. 2017;151(1):60–7. https://doi.org/10.1016/j.chest.2016.08.001 .
Kawayama T, Hoshino T, Ichiki M, Tsuda T, Kinoshita M, Takata S, Koga T, Iwanaga T, Aizawa H, Kurume CSG. Effect of add-on therapy of tiotropium in COPD treated with theophylline. Int J Chronic Obstr Pulm Dis. 2008;3(1):137–47.
Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med. 2009;180(1):3–10. https://doi.org/10.1164/rccm.200901-0047OC .
Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435–59. https://doi.org/10.1146/annurev.pathol.4.110807.092145 .
Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ. 1988;297(6662):1506–10.
Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med. 1995;151(6):1907–14. https://doi.org/10.1164/ajrccm.151.6.7767539 .
Barnes PJ. Theophylline. Am J Respir Crit Care Med. 2013;188(8):901–6. https://doi.org/10.1164/rccm.201302-0388PP .
Tsukagoshi H, Shimizu Y, Iwamae S, Hisada T, Ishizuka T, Iizuka K, Dobashi K, Mori M. Evidence of oxidative stress in asthma and COPD: potential inhibitory effect of theophylline. Respir Med. 2000;94(6):584–8. https://doi.org/10.1053/rmed.2000.0785 .
Culpitt SV, de Matos C, Russell RE, Donnelly LE, Rogers DF, Barnes PJ. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;165(10):1371–6.